



# Half Yearly Report 2010

 **BEACON**  
Pharmaceuticals Limited  
*a company with global vision*

### **Vision**

To be regarded and recognized as one of the most value-driven pharmaceutical companies in the world.

### **Mission**

To improve the quality of human life by providing innovative pharmaceutical products through continuous research and development and by ensuring stakeholders satisfaction.

### **Objectives**

- Consistent improve our product lines and provide unsurpassed service to our nation.
- Create sustainable economic value for shareholders.
- Provide motivating work, extensive opportunities for learning and career development, competitive pay and benefits and flexible environment where diversity is valued.
- Conduct business in a socially responsible manner
- Improve ethical and business standard of corporate governance.

### **Goals**

Understand the nation's needs and to save the nations life, diversified product is to be produced and convey at a affordable price. By doing so to benefit our shareholders, employee and the community where we do business.

### **Strategic priorities**

- Strong fundamentals
- Concentration to core businesses
- Products diversification
- Superior client services
- Market position
- More competitive

**Dear Shareholders**

We are pleased to present the un-audited Financial Statements for the half year ended 31st December 2010 of the company containing Balance Sheet, Income Statement, Statement of Changes in Equity and Cash Flow Statement thereof.



**Md. Ebadul Karim**  
Managing Director

**BEACON PHARMACEUTICALS LTD.**  
153-154, Tejgaon Industrial Area, Dhaka-1208  
**BALANCE SHEET AS AT 31ST DECEMBER 2010**

<b>ASSETS</b>	<b>31 Dec 2010</b>	<b>30 Jun 2010</b>
<b>Non-Current Assets</b>		
Property, Plant & Equipment	<b>2,625,321,458</b>	2,529,426,272
Deferred IPO Expenses	<b>21,304,937</b>	-
<b>Current Assets</b>	<b>1,462,673,961</b>	1,120,732,011
Inventories	<b>885,514,174</b>	667,168,268
Accounts Receivables	<b>82,329,797</b>	68,041,157
Advance, Deposits & Pre-payments	<b>447,305,047</b>	358,910,015
Cash & Bank Balances	<b>47,524,943</b>	26,612,571
Investment in Shares	<b>2,000,000</b>	2,000,000
<b>TOTAL ASSETS</b>	<b>Tk. 4,111,300,356</b>	3,652,158,283
<b>SHAREHOLDERS' EQUITY &amp; LIABILITIES</b>		
<b>Shareholders' Equity</b>	<b>2,664,980,050</b>	2,286,852,753
Issued Capital	<b>2,200,000,000</b>	1,900,000,000
Reserve and Surplus	<b>382,861,379</b>	386,631,629
Share Money Deposit	-	-
Retained Earnings	<b>82,118,671</b>	221,124
<b>Non-Current Liabilities</b>	<b>990,577,321</b>	940,488,185
Long Term Borrowings - Net off Current Maturity Liability for EWF and WPPF	<b>985,659,681</b>	938,784,335
	<b>4,917,640</b>	1,703,850
<b>Current Liabilities</b>	<b>455,742,985</b>	424,817,345
Short Term Borrowings	<b>270,685,676</b>	262,854,378
Long Term Borrowings -Current Maturity	<b>134,601,122</b>	134,601,122
Share Application Money (Refundable)	<b>14,955,842</b>	-
Accounts Payables	<b>18,828,598</b>	17,800,174
Tax Payable	<b>8,311,477</b>	254,225
Accrued Expenses	<b>8,360,270</b>	9,307,446
<b>TOTAL SHAREHOLDERS' EQUITY &amp; LIABILITIES</b>	<b>Tk. 4,111,300,356</b>	3,652,158,283
Net Asset Value (NAV) per share	<b>12.11</b>	12.04



**Company Secretary**



**Managing Director**

**BEACON PHARMACEUTICALS LTD.**  
153-154, Tejgaon Industrial Area, Dhaka-1208

**Income Statement**  
For the half year ended 31st December 2010

Particulars	Jul-Dec'10 Half Year	Jul-Dec'09 Half Year	Oct-Dec'10 2nd Qtr	Oct-Dec'09 2nd Qtr
<b>Turnover</b>	<b>329,870,770</b>	259,478,688	<b>158,014,602</b>	136,661,256
<b>Less : Cost of Goods Sold</b>	<b>144,074,913</b>	115,116,674	<b>66,591,436</b>	58,382,837
<b>Gross Profit</b>	<b>185,795,857</b>	144,362,014	<b>91,423,166</b>	78,278,419
Less : Administrative Expenses	<b>11,751,270</b>	10,251,633	<b>5,769,850</b>	5,274,835
Less : Selling, Marketing & Distribution Expenses	<b>48,976,409</b>	42,298,708	<b>23,649,958</b>	21,478,155
	<b>60,727,679</b>	52,550,341	<b>29,419,808</b>	26,752,989
<b>Operating Income</b>	<b>125,068,178</b>	91,811,673	<b>62,003,358</b>	51,525,429
Less : Financial Expenses	<b>84,815,249</b>	94,958,405	<b>43,685,252</b>	46,022,308
<b>Net Profit after Financial Expenses</b>	<b>40,252,929</b>	(3,146,732)	<b>18,318,106</b>	5,503,121
Income from other Sources	<b>52,210,772</b>	4,080,688	<b>19,500,043</b>	4,080,688
<b>Net Profit before IPO Expenses</b>	<b>92,463,701</b>	933,956	<b>37,818,149</b>	9,583,809
Deffered IPO Expenses	<b>2,367,216</b>	-	<b>1,183,608</b>	-
<b>Net Profit before contribution to WPPF</b>	<b>90,096,485</b>	933,956	<b>36,634,541</b>	9,583,809
Less : Contribution to WPPF	<b>4,290,309</b>	-	<b>1,744,502</b>	-
<b>Net Profit before Taxation</b>	<b>85,806,176</b>	933,956	<b>34,890,039</b>	9,583,809
Income Tax	<b>7,678,879</b>	-	<b>7,678,879</b>	-
<b>Net Profit after Taxation Tk.</b>	<b>78,127,297</b>	933,956	<b>27,211,160</b>	9,583,809
<b>Earning Per Share (EPS)</b>	<b>0.36</b>	0.005	<b>0.12</b>	0.05
<b>Nos. of Shares Issued</b>	<b>220,000,000</b>	190,000,000	<b>220,000,000</b>	190,000,000



Company Secretary



Managing Director

**STATEMENT OF CHANGES IN EQUITY**

For the half year ended 31st December 2010

Particulars	Share Capital	Revaluation Reserve	Tax holiday Reserve	Retained Earnings	Total Equity
At the beginning of the period	1,900,000,000	384,220,144	2,411,485	221,124	2,286,852,753
Net profit/(Loss) transferred from the Profit & Loss Account	-	-	-	78,127,297	78,127,297
Revaluation Reserve adjustment	-	(8,861,864)	-	8,861,864	-
Transferred to Tax holiday Reserve	-	-	5,091,614	(5,091,614)	-
Capital issued during the period	300,000,000	-	-	-	300,000,000
<b>At the end of the period</b>	<b>Tk. 2,200,000,000</b>	<b>375,358,280</b>	<b>7,503,099</b>	<b>82,118,671</b>	<b>2,664,980,050</b>

**STATEMENT OF CHANGES IN EQUITY**

For the half year ended 31st December 2009

Particulars	Share Capital	Revaluation Reserve	Tax holiday Reserve	Retained Earnings	Total Equity
At the beginning of the period	600,000,000	401,943,872	-	(39,205,969)	962,737,903
Net profit/(Loss) transferred from the Profit & Loss Account	-	-	-	933,956	933,956
Revaluation Reserve adjustment	-	(8,861,864)	-	8,861,864	-
Capital issued during the period	1,300,000,000	-	-	-	1,300,000,000
<b>At the end of the period</b>	<b>Tk. 1,900,000,000</b>	<b>393,082,008</b>	<b>-</b>	<b>(29,410,149)</b>	<b>2,263,671,859</b>



Company Secretary



Managing Director

**BEACON PHARMACEUTICALS LTD.**  
153-154, Tejgaon Industrial Area, Dhaka-1208

**Cash Flow Statement**  
For the half year ended 31st December 2010

Particulars	Jul-Dec'10 Half Year	Jul-Dec'09 Half Year
<b>Cash Flows from Operating Activities :</b>		
Collection against Sales	315,582,130	252,490,000
Payment to Creditors and Employees	(260,832,325)	(133,466,513)
Other Operating Expenses	(81,407,430)	(71,901,864)
Interest paid	(20,522,837)	(17,750,158)
<b>Net Cash Generated from Operating Activities</b>	<b>(47,180,462)</b>	29,371,465
<b>Cash Flows from Investing Activities :</b>		
Acquisition of Property, Plant & Equipment	(177,420,827)	(31,835,864)
Disposal of Property, Plant & Equipment	-	-
Investment in Shares	-	(2,000,000)
Interest and Other Received	52,210,772	4,080,688
Payment to others	(88,395,032)	(254,242,952)
<b>Net Cash Generated from Investing Activities</b>	<b>(213,605,087)</b>	(283,998,128)
<b>Cash Flows from Financing Activities :</b>		
Capital Received	300,000,000	1,300,000,000
IPO Expenses (Current & Deferred)	(23,672,153)	-
Excess Share Application Money Refunded	14,955,842	-
Long Term Loan Received	-	-
Long Term Loan Refund	(17,417,066)	(478,277,000)
Short Term Loan Received	268,414,326	-
Short Term Loan Refund	(260,583,028)	(212,429,248)
<b>Net Cash Generated from Financing Activities</b>	<b>281,697,921</b>	609,293,752
<b>Net Cash Increase / (Decrease)</b>	<b>20,912,372</b>	354,667,089
Cash and Cash Equivalents - Opening	26,612,571	5,772,633
<b>Cash and Cash Equivalents - Closing</b>	<b>47,524,943</b>	360,439,722
<b>Operating Cash Flow per share</b>	<b>(0.21)</b>	0.15
<b>Nos. of Shares Issued</b>	<b>220,000,000</b>	190,000,000



Company Secretary



Managing Director

## CORPORATE INFORMATION

### Corporate Headquarters

153-154 Tejgaon I/A, Dhaka 1208. Bangladesh.  
Tel : + 880-2-9888176, + 880-2-8822543  
Fax : + 880-2-8829314  
E-mail : beacon@beacon-pharma.com  
Webside : www.beacon-pharma.com

### Legal Advisor

Abul Khayer & Associates  
25/A Indira Road, Farmgate, Dhaka.

### Auditors

Malek Siddiqui Wali  
Chartered Accountants  
9-G, Motijheel C/A, Dhaka-1000.

### Company Secretary

Anjan Mallik, M.Com, ACA  
Company Secretary  
Tel : + 880-2-9888176, + 880-2-8822543  
Fax : + 880-2-8829314

### Factory

Kathali, Bhaluka, Mymensing.

### Stock Exchange Listing

Dhaka Stock Exchange Ltd.  
Chittagong Stock Exchange Ltd.

### Banker

Janata Bank Limited  
Principal Branch, Dhaka.



**BEACON**  
Pharmaceuticals Limited  
*a company with global vision*

[www.beacon-pharma.com](http://www.beacon-pharma.com)